.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, individuals with metastatic intestinal growths who acquired biomarker-matched treatments based upon circulating lump DNA profiling revealed a higher professional perk than those getting incomparable therapy.